Chowning is a composer, musician and professor that had a seismic impact on both the development of music technology and the ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

The Phase 1 clinical trial, STRIKE-001 (NCT07103018), is a multi-center, open-label dose escalation of KTX-2001 monotherapy (Part A) and in combination with darolutamide, an oral, nonsteroidal ...

Dewpoint Therapeutics, Inc., a clinical-stage biotechnology company pioneering condensate-modulating therapeutics, today announced that the first patient has been dosed in a Phase 1a/2a clinical trial ...

Researchers at the Institute for Molecular Science (NINS, Japan) and SOKENDAI have demonstrated a more than 2000% voltage-induced enhancement of near-field nonlinear optical responses. To achieve this ...

LCGC International salutes Jack Henion and Bob W.J. Pirok, winners of the 19th annual LCGC Lifetime Achievement and Emerging ...

A U.S. commercial-stage oncology company focused on immuno-oncology medicines. It markets LOQTORZI (toripalimab-tpzi) and is advancing a small clinical pipeline of antibody programs targeting the ...

Medications targeting the neonatal fragment crystallizable receptor have gained attention due to multiple recent FDA ...

Publication presents clinical findings highlighting evenamide’s glutamatergic modulation as a therapeutic strategy for patients with inadequate response or treatment-resistant schizophrenia (TRS) By ...

Mouser Electronics has announced a new Interactive Ebook in collaboration with Renesas Electronics that explores how data ...

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the l ...

Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that ...